Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al
Their high cost, broad potential use, and long-term treatment needs are creating significant financial concerns for employers covering these drugs for weight management
doi:10.1016/j.peptides.2019.170197 332
The Phase 3 TRIUMPH-4 trial (68 weeks) reported topline results in December 2025
Peer-reviewed research has investigated AOD-9604 across animal models, ex vivo adipose tissue assays, and human clinical trials , with published studies appearing in journals including Endocrinology , the American Journal of Physiology Endocrinology and Metabolism , and Hormone Research
GLP-1 receptor agonist therapy and reduced incidence of rheumatic diseases: A propensity score-matched cohort study